View Item 

Show simple item record

Peritransplant palifermin use and lymphocyte recovery after T‐cell replete, matched related allogeneic hematopoietic cell transplantation

dc.contributor.authorRizwan, Romeeen_US
dc.contributor.authorLevine, John E.en_US
dc.contributor.authorDeFor, Todden_US
dc.contributor.authorFerarra, James L.M.en_US
dc.contributor.authorWeisdorf, Daniel J.en_US
dc.contributor.authorBlazar, Bruce R.en_US
dc.contributor.authorVerneris, Michael R.en_US
dc.date.accessioned2011-11-10T15:35:40Z
dc.date.available2012-12-03T21:17:30Zen_US
dc.date.issued2011-10en_US
dc.identifier.citationRizwan, Romee; Levine, John E.; DeFor, Todd; Ferarra, James L.M.; Weisdorf, Daniel J.; Blazar, Bruce R.; Verneris, Michael R. (2011). "Peritransplant palifermin use and lymphocyte recovery after T‐cell replete, matched related allogeneic hematopoietic cell transplantation ." American Journal of Hematology 86(10): 879-882. <http://hdl.handle.net/2027.42/86994>en_US
dc.identifier.issn0361-8609en_US
dc.identifier.issn1096-8652en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/86994
dc.publisherWiley Subscription Services, Inc., A Wiley Companyen_US
dc.titlePeritransplant palifermin use and lymphocyte recovery after T‐cell replete, matched related allogeneic hematopoietic cell transplantationen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMolecular, Cellular and Developmental Biologyen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.subject.hlbtoplevelScienceen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumThe Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherThe Blood and Marrow Transplantation Program, University of Minnesota, Minneapolisen_US
dc.contributor.affiliationotherDepartment of Pediatrics, Division of Hematology/Oncology and Blood and Marrow Transplantation, University of Minnesota, 660 CCRB, 425 East River Road, Minneapolis, MN 55455E‐mail: verneris@umn.eduen_US
dc.identifier.pmid21922528en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/86994/1/22136_ftp.pdf
dc.identifier.doi10.1002/ajh.22136en_US
dc.identifier.sourceAmerican Journal of Hematologyen_US
dc.identifier.citedreferenceBallen KK, King RJ, Chitphakdithai P, et al. The national marrow donor program 20 years of unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008; 14: 2 – 7.en_US
dc.identifier.citedreferenceShilling HG, McQueen KL, Cheng NW, et al. Reconstitution of NK cell receptor repertoire following HLA‐matched hematopoietic cell transplantation. Blood 2003; 101: 3730 – 3740.en_US
dc.identifier.citedreferenceTriplett BM, Horwitz EM, Iyengar R, et al. Effects of activating NK cell receptor expression and NK cell reconstitution on the outcomes of unrelated donor hematopoietic cell transplantation for hematologic malignancies. Leukemia 2009; 23: 1278 – 1287.en_US
dc.identifier.citedreferenceDouek DC, Vescio RA, Betts MR, et al. Assessment of thymic output in adults after haematopoietic stem‐cell transplantation and prediction of T‐cell reconstitution. Lancet 2000; 355: 1875 – 1881.en_US
dc.identifier.citedreferenceHeitger A, Neu N, Kern H, et al. Essential role of the thymus to reconstitute naive (CD45RA+) T‐helper cells after human allogeneic bone marrow transplantation. Blood 1997; 90: 850 – 857.en_US
dc.identifier.citedreferenceMarie‐Cardine A, Divay F, Dutot I, et al. Transitional B cells in humans: Characterization and insight from B lymphocyte reconstitution after hematopoietic stem cell transplantation. Clin Immunol 2008; 127: 14 – 25.en_US
dc.identifier.citedreferenceCooley S, McCullar V, Wangen R, et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 2005; 106: 4370 – 4376.en_US
dc.identifier.citedreferenceSzabolcs P, Niedzwiecki D. Immune reconstitution after unrelated cord blood transplantation. Cytotherapy 2007; 9: 111 – 122.en_US
dc.identifier.citedreferenceBurke MJ, Vogel RI, Janardan SK, et al. Early lymphocyte recovery and outcomes after umbilical cord blood transplantation (UCBT) for hematologic malignancies. Biol Blood Marrow Transplant 2011; 17: 831 – 840.en_US
dc.identifier.citedreferencePavletic ZS, Joshi SS, Pirruccello SJ, et al. Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies. Bone Marrow Transplant 1998; 21: 33 – 41.en_US
dc.identifier.citedreferenceLe Blanc K, Barrett AJ, Schaffer M, et al. Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies. Biol Blood Marrow Transplant 2009; 15: 1108 – 1115.en_US
dc.identifier.citedreferenceKumar S, Chen MG, Gastineau DA, et al. Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia. Leukemia 2003; 17: 1865 – 1870.en_US
dc.identifier.citedreferenceKumar S, Chen MG, Gastineau DA, et al. Effect of slow lymphocyte recovery and type of graft‐versus‐host disease prophylaxis on relapse after allogeneic bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 2001; 28: 951 – 956.en_US
dc.identifier.citedreferenceIshaqi MK, Afzal S, Dupuis A, et al. Early lymphocyte recovery post‐allogeneic hematopoietic stem cell transplantation is associated with significant graft‐versus‐leukemia effect without increase in graft‐versus‐host disease in pediatric acute lymphoblastic leukemia. Bone Marrow Transplant 2008; 41: 245 – 252.en_US
dc.identifier.citedreferenceKim DH, Kim JG, Sohn SK, et al. Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation. Br J Haematol 2004; 125: 217 – 224.en_US
dc.identifier.citedreferenceKelly RM, Goren EM, Taylor PA, et al. Short‐term inhibition of p53 combined with keratinocyte growth factor improves thymic epithelial cell recovery and enhances T‐cell reconstitution after murine bone marrow transplantation. Blood 2010; 115: 1088 – 1097.en_US
dc.identifier.citedreferenceRossi SW, Jeker LT, Ueno T, et al. Keratinocyte growth factor (KGF) enhances postnatal T‐cell development via enhancements in proliferation and function of thymic epithelial cells. Blood 2007; 109: 3803 – 3811.en_US
dc.identifier.citedreferenceMin D, Taylor PA, Panoskaltsis‐Mortari A, et al. Protection from thymic epithelial cell injury by keratinocyte growth factor: A new approach to improve thymic and peripheral T‐cell reconstitution after bone marrow transplantation. Blood 2002; 99: 4592 – 4600.en_US
dc.identifier.citedreferenceMin D, Panoskaltsis‐Mortari A, Kuro OM, et al. Sustained thymopoiesis and improvement in functional immunity induced by exogenous KGF administration in murine models of aging. Blood 2007; 109: 2529 – 2537.en_US
dc.identifier.citedreferenceNapolitano LA, Schmidt D, Gotway MB, et al. Growth hormone enhances thymic function in HIV‐1‐infected adults. J Clin Invest 2008; 118: 1085 – 1098.en_US
dc.identifier.citedreferenceErickson M, Morkowski S, Lehar S, et al. Regulation of thymic epithelium by keratinocyte growth factor. Blood 2002; 100: 3269 – 3278.en_US
dc.identifier.citedreferenceAlpdogan O, Hubbard VM, Smith OM, et al. Keratinocyte growth factor (KGF) is required for postnatal thymic regeneration. Blood 2006; 107: 2453 – 2460.en_US
dc.identifier.citedreferenceRossi S, Blazar BR, Farrell CL, et al. Keratinocyte growth factor preserves normal thymopoiesis and thymic microenvironment during experimental graft‐versus‐host disease. Blood 2002; 100: 682 – 691.en_US
dc.identifier.citedreferenceSeggewiss R, Lore K, Guenaga FJ, et al. Keratinocyte growth factor augments immune reconstitution after autologous hematopoietic progenitor cell transplantation in rhesus macaques. Blood 2007; 110: 441 – 449.en_US
dc.identifier.citedreferenceKelly RM, Highfill SL, Panoskaltsis‐Mortari A, et al. Keratinocyte growth factor and androgen blockade work in concert to protect against conditioning regimen‐induced thymic epithelial damage and enhance T‐cell reconstitution after murine bone marrow transplantation. Blood 2008; 111: 5734 – 5744.en_US
dc.identifier.citedreferenceBlazar BR, Weisdorf DJ, Defor T, et al. Phase 1/2 randomized, placebo‐control trial of palifermin to prevent graft‐versus‐host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 2006; 108: 3216 – 3222.en_US
dc.identifier.citedreferenceLevine JE, Blazar BR, DeFor T, et al. Long‐term follow‐up of a phase I/II randomized, placebo‐controlled trial of palifermin to prevent graft‐versus‐host disease (GVHD) after related donor allogeneic hematopoietic cell transplantation (HCT). Biol Blood Marrow Transplant 2008; 14: 1017 – 1021.en_US
dc.identifier.citedreferenceSavani BN, Mielke S, Rezvani K, et al. Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell‐depleted allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 1216 – 1223.en_US
dc.identifier.citedreferenceSeggewiss R, Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: An update. Blood 2010; 115: 3861 – 3868.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
22136_ftp.pdf
Size:
1.418MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.